Illumina Inc

ILMN Real Time Price USD
N/A
N/A
N/A
...
...
Overview
Financials
Forecast
Insiders
Institutions
Compensation
Government
Ownership
News

Chart provided by TradingView

Income
Balance Sheet
Cash Flow
Revenue Breakdown
Congress Trading

Recent trades of ILMN by members of U.S. Congress

Politician Type Traded
Ro Khanna House / D Sale $1,001 - $15,000 Jan 29, 2026
Lisa C. McClain House / R Sale $1,001 - $15,000 Oct 31, 2025
Lisa C. McClain House / R Purchase $1,001 - $15,000 Oct 30, 2025
Lisa C. McClain House / R Sale $1,001 - $15,000 Oct 30, 2025
Lisa C. McClain House / R Purchase $1,001 - $15,000 Jun 09, 2025
Thomas H. Kean, Jr. House / R Purchase $1,001 - $15,000 Apr 01, 2025
Thomas H. Kean, Jr. House / R Purchase $1,001 - $15,000 Apr 01, 2025
Ro Khanna House / D Sale $1,001 - $15,000 Feb 25, 2025
Michael C. Burgess House / R Sale $15,001 - $50,000 Sep 03, 2024
Michael C. Burgess House / R Sale $15,001 - $50,000 Aug 30, 2024
Ro Khanna House / D Sale $1,001 - $15,000 Jul 02, 2024
Ro Khanna House / D Purchase $1,001 - $15,000 May 29, 2024
Ro Khanna House / D Sale $1,001 - $15,000 May 28, 2024
Thomas H. Kean, Jr. House / R Purchase $1,001 - $15,000 Apr 19, 2024
Michael C. Burgess House / R Sale $1,001 - $15,000 Mar 11, 2024
Michael C. Burgess House / R Sale $1,001 - $15,000 Mar 11, 2024
Michael C. Burgess House / R Sale $1,001 - $15,000 Feb 12, 2024
Michael C. Burgess House / R Sale $1,001 - $15,000 Feb 12, 2024
Michael C. Burgess House / R Purchase $15,001 - $50,000 Feb 12, 2024
Michael C. Burgess House / R Purchase $15,001 - $50,000 Jan 02, 2024
Michael C. Burgess House / R Purchase $1,001 - $15,000 Jan 02, 2024
Michael C. Burgess House / R Sale $1,001 - $15,000 Jan 02, 2024
Ro Khanna House / D Purchase $1,001 - $15,000 Dec 05, 2023
Ro Khanna House / D Sale $1,001 - $15,000 Nov 03, 2023
Ro Khanna House / D Purchase $1,001 - $15,000 Oct 31, 2023
Ro Khanna House / D Purchase $1,001 - $15,000 Oct 02, 2023
Ro Khanna House / D Sale $1,001 - $15,000 Aug 29, 2023
Ro Khanna House / D Purchase $1,001 - $15,000 Jul 28, 2023
Ro Khanna House / D Sale $1,001 - $15,000 Jun 29, 2023
Ro Khanna House / D Sale $1,001 - $15,000 Jun 26, 2023
Ro Khanna House / D Sale $1,001 - $15,000 May 04, 2023
Ro Khanna House / D Sale $1,001 - $15,000 Apr 10, 2023
Ro Khanna House / D Purchase $1,001 - $15,000 Mar 14, 2023
Ro Khanna House / D Sale $1,001 - $15,000 Feb 10, 2023
Ro Khanna House / D Sale $15,001 - $50,000 Dec 05, 2022
Ro Khanna House / D Purchase $1,001 - $15,000 Aug 23, 2022
Ro Khanna House / D Sale $15,001 - $50,000 N/A
Ro Khanna House / D Purchase $1,001 - $15,000 Jul 19, 2022
Ro Khanna House / D Purchase $1,001 - $15,000 Jun 17, 2022
Kathy E. Manning House / D Sale $15,001 - $50,000 Jun 10, 2022
Ro Khanna House / D Sale $15,001 - $50,000 N/A
Ro Khanna House / D Sale $15,001 - $50,000 May 23, 2022
Ro Khanna House / D Sale $1,001 - $15,000 May 10, 2022
Ro Khanna House / D Purchase $1,001 - $15,000 N/A
Ro Khanna House / D Purchase $1,001 - $15,000 N/A
Ro Khanna House / D Purchase $1,001 - $15,000 N/A
Ro Khanna House / D Purchase $1,001 - $15,000 May 05, 2022
Ro Khanna House / D Sale $1,001 - $15,000 May 05, 2022
Ro Khanna House / D Purchase $1,001 - $15,000 Apr 13, 2022
Ro Khanna House / D Sale $1,001 - $15,000 N/A
ILMN Stock Insider Trading Activity Follow @QuiverQuant for major insider updates
Closing Price
Purchase
Sale
Name
Type
Shares
Price
Shares Held
Date
Reported
ILMN Stock Institutional Owners
Investor
Shares
Change in Shares
Market Value
Date
Reported
ILMN Derivatives Institutional Owners
Investor
Type
Shares
Change in Shares
Market Value
Date
Reported
Whale Activity

Recently reported changes in ILMN holdings by institutional investors

Insider Trading

Quarterly net insider trading by ILMN's directors and management

* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.

About

Backtest Start Date
CAGR (Total)
Return (30d)
Return (1Y)
View Strategy Copytrade Strategy
  • 1M
  • 3M
  • 6M
  • YTD
  • 1Y
  • 2Y
  • 5Y
  • MAX

About

Backtest Start Date

Key Metrics

Return (1d)

Return (30d)

Return (1Y)

CAGR (Total)

Max Drawdown

Beta

Alpha

Sharpe Ratio

Win Rate

Average Win

Average Loss

Annual Volatility

Annual Std Dev

Information Ratio

Treynor Ratio

Total Trades

Show More
Metrics Definitions

Disclaimer: The performance results shown are based on historical backtesting and are hypothetical in nature. Backtested performance does not represent actual trading and does not account for all market factors that may affect execution, such as liquidity, slippage, and changing market conditions. Past performance is not necessarily indicative of future results. There is no guarantee that any trading strategy will be profitable or avoid losses.

  • Alpha

    Measures a portfolio's risk-adjusted performance against that of its benchmark

    Learn More about Alpha
  • Annual Standard Deviation

    Measures how much the portfolio's total return varies from its mean or average.

    Learn More about Annual Standard Deviation
  • Annual Volatility

    A statistical measure of the dispersion of returns for the portfolio.

    Learn More about Annual Volatility
  • Average Win

    The average return (%) for trades that resulted in a positive return.

  • Average Loss

    The average return (%) for trades that resulted in a negative return.

  • Beta

    A measure of the volatility of the portfolio compared to the market as a whole.

    Learn More about Beta
  • CAGR

    CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.

    Learn More about CAGR
  • Information Ratio

    A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.

    Learn More about Information Ratio
  • Max Drawdown

    the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.

    Learn More about Max Drawdown
  • Sharpe Ratio

    The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.

    Learn More about Sharpe Ratio
  • Total Trades

    The total number of trades made by this strategy.

  • Treynor Ratio

    Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.

    Learn More about Treynor Ratio
  • Win Rate

    The percentage of total trades that resulted in a positive return.

Subscribe to Quiver Premium for insider trading alerts

Be the first to see our newest insights and key updates across all datasets.

See Pricing
schema-2
Corporate Lobbying

Government lobbying spending instances

  • $330,000 Jan 20, 2026 Issue: None
  • $380,000 Oct 20, 2025 Issue: Health Issues Taxation/Internal Revenue Code Trade (domestic/foreign)
  • $410,000 Jul 21, 2025 Issue: Budget/Appropriations Health Issues Taxation/Internal Revenue Code Trade (domestic/foreign)
  • $620,000 May 08, 2025 Issue: Budget/Appropriations Health Issues Homeland Security
  • $400,000 Jan 21, 2025 Issue: Budget/Appropriations Health Issues Defense
  • $280,000 Dec 12, 2024 Issue: Budget/Appropriations Defense Health Issues
  • $270,000 Jul 22, 2024 Issue: Defense Trade (domestic/foreign) Health Issues
  • $510,000 Jan 22, 2024 Issue: Defense Trade (domestic/foreign) Government Issues Health Issues
  • $420,000 Oct 20, 2023 Issue: Defense Trade (domestic/foreign) Government Issues Health Issues
  • $1,460,000 Jul 20, 2023 Issue: Defense Trade (domestic/foreign) Government Issues Health Issues
  • $1,300,000 Jan 20, 2023 Issue: Trade (domestic/foreign) Government Issues Health Issues
  • $1,380,000 Oct 20, 2022 Issue: Trade (domestic/foreign) Government Issues Health Issues
  • $1,690,000 Jul 20, 2022 Issue: Trade (domestic/foreign) Government Issues Health Issues
  • $1,960,000 Apr 20, 2022 Issue: Government Issues Health Issues
  • $820,000 Jan 20, 2022 Issue: Government Issues
  • $10,000 Jan 20, 2022 Issue: Government Issues
  • $60,000 Jan 20, 2022 Issue: Health Issues
  • $50,000 Jan 20, 2022 Issue: None
  • $40,000 Jan 20, 2022 Issue: Labor Issues/Antitrust/Workplace Medicare/Medicaid Health Issues
  • $50,000 Jan 20, 2022 Issue: Health Issues
  • $60,000 Jan 19, 2022 Issue: Health Issues
  • $320,000 Jan 19, 2022 Issue: Health Issues Government Issues
  • $10,000 Oct 28, 2021 Issue: Government Issues
  • $920,000 Oct 21, 2021 Issue: Government Issues
  • $60,000 Oct 20, 2021 Issue: Health Issues
  • $50,000 Oct 20, 2021 Issue: None
  • $40,000 Oct 20, 2021 Issue: Medicare/Medicaid Health Issues Labor Issues/Antitrust/Workplace
  • $10,000 Oct 19, 2021 Issue: Government Issues
  • $50,000 Oct 19, 2021 Issue: Health Issues
  • $375,000 Oct 18, 2021 Issue: Health Issues Government Issues
  • $20,000 Jul 29, 2021 Issue: Health Issues
  • $60,000 Jul 20, 2021 Issue: Health Issues Labor Issues/Antitrust/Workplace
  • $40,000 Jul 20, 2021 Issue: Labor Issues/Antitrust/Workplace Health Issues Veterans Medicare/Medicaid
  • $40,000 Jul 20, 2021 Issue: Government Issues
  • $150,000 Jul 19, 2021 Issue: Health Issues Government Issues
  • $50,000 Jul 19, 2021 Issue: Trade (domestic/foreign)
  • $290,000 Apr 20, 2021 Issue: None
  • $270,000 Jan 21, 2021 Issue: None
  • $270,000 Oct 20, 2020 Issue: None
  • $170,000 Jul 20, 2020 Issue: None
  • $180,000 Apr 20, 2020 Issue: HEALTH ISSUES
  • $190,000 Jan 21, 2020 Issue: None
  • $160,000 Oct 21, 2019 Issue: Budget/Appropriations Health Issues
  • $160,000 Jul 22, 2019 Issue: Budget/Appropriations Health Issues
  • $130,000 Apr 22, 2019 Issue: Health Issues Budget/Appropriations
  • $60,000 Jan 22, 2019 Issue: Health Issues
  • $60,000 Oct 22, 2018 Issue: Health Issues
  • $70,000 Jul 20, 2018 Issue: Health Issues
  • $100,000 Apr 20, 2018 Issue: Medicare/Medicaid Budget/Appropriations
  • $50,000 Jan 19, 2018 Issue: Medical/Disease Research/Clinical Labs Medicare/Medicaid Budget/Appropriations
  • $50,000 Oct 20, 2017 Issue: Medical/Disease Research/Clinical Labs Medicare/Medicaid Budget/Appropriations
  • $50,000 Jul 20, 2017 Issue: Medical/Disease Research/Clinical Labs Budget/Appropriations Medicare/Medicaid
  • $40,000 Apr 18, 2017 Issue: Medical/Disease Research/Clinical Labs
  • $45,000 Jan 13, 2017 Issue: Health Issues
  • $45,000 Oct 19, 2016 Issue: Health Issues
  • $60,000 Jul 20, 2016 Issue: Health Issues
  • $90,000 Apr 20, 2016 Issue: Health Issues
  • $20,000 Jan 20, 2016 Issue: Health Issues
  • $40,000 Jan 18, 2013 Issue: Homeland Security Science/Technology Defense
Corporate Lobbying

ILMN Estimated quarterly lobbying spending

Revenue Breakdown

ILMN Revenue by Segment or Geography

By Segment
By Geography
ILMN Income Statement
ILMN Balance Sheet
ILMN Cash Flow
U.S. Patents

New ILMN patent grants

  • Patent Title: Sequencing instrument Oct. 18, 2022
  • Patent Title: Display screen with a graphical user interface Oct. 04, 2022
  • Patent Title: Flow cell device Aug. 30, 2022
  • Patent Title: Display screen or portion thereof with graphical user interface Aug. 02, 2022
  • Patent Title: Display screen or portion thereof with graphical user interface Jul. 05, 2022
  • Patent Title: Display screen or portion thereof with graphical user interface Jul. 05, 2022
  • Patent Title: Display screen or portion thereof with graphical user interface Jul. 05, 2022
  • Patent Title: Flow cell cartridge May. 31, 2022
  • Patent Title: Flow cell cartridge May. 31, 2022
  • Patent Title: Flow cell cartridge May. 31, 2022
  • Patent Title: Sequencing instrument light visor May. 24, 2022
  • Patent Title: Sequencing cartridge assembly May. 24, 2022
  • Patent Title: Reagent cartridge Apr. 19, 2022
  • Patent Title: Reagent cartridge Jan. 25, 2022
  • Patent Title: Reagent cartridge Jan. 25, 2022
  • Patent Title: Display screen with a graphical user interface Jan. 11, 2022
  • Patent Title: Display screen or portion thereof with graphical user interface Oct. 05, 2021
  • Patent Title: Light visor for sequencing instrument Jul. 20, 2021
  • Patent Title: Sequencing instrument Jun. 22, 2021
  • Patent Title: Sequencing instrument Jun. 22, 2021
  • Patent Title: Flowcell cartridge May. 11, 2021
  • Patent Title: Display screen or portion thereof with graphical user interface icon Mar. 23, 2021
  • Patent Title: Reagent cartridge Mar. 16, 2021
  • Patent Title: Portion of analysis unit Dec. 15, 2020
  • Patent Title: Display screen or portion thereof with graphical user interface Sep. 15, 2020
  • Patent Title: Display screen or portion thereof with graphical user interface Sep. 08, 2020
  • Patent Title: Reagent cartridge Sep. 01, 2020
  • Patent Title: Display screen with a graphical user interface Sep. 01, 2020
  • Patent Title: Display screen or portion thereof with graphical user interface Feb. 18, 2020
  • Patent Title: Display screen or portion thereof with animated graphical user interface Jan. 21, 2020
  • Patent Title: Display screen or portion thereof with graphical user interface Dec. 10, 2019
  • Patent Title: Display screen or portion thereof with zygosity icon Nov. 19, 2019
  • Patent Title: Display screen or portions thereof with graphical user interface Nov. 05, 2019
  • Patent Title: Multi-hole cartridge Oct. 29, 2019
  • Patent Title: Cartridge Oct. 29, 2019
  • Patent Title: Cartridge chassis Oct. 22, 2019
  • Patent Title: Display screen with a graphical user interface Oct. 15, 2019
  • Patent Title: Cartridge package Oct. 01, 2019
  • Patent Title: Library tube Sep. 17, 2019
  • Patent Title: Display screen or portion thereof with graphical user interface icon Aug. 27, 2019
  • Patent Title: Sequencing instrument display screen or portion thereof with graphical user interface icon Aug. 27, 2019
  • Patent Title: Flowcell cartridge Aug. 20, 2019
  • Patent Title: Full flowcell cartridge Aug. 20, 2019
  • Patent Title: Flowcell cartridge Aug. 13, 2019
  • Patent Title: Analysis unit Aug. 06, 2019
  • Patent Title: Multi-chamber bottle May. 28, 2019
  • Patent Title: Sequencing or sample preparation instrument May. 07, 2019
  • Patent Title: Sample preparation cartridge Mar. 12, 2019
  • Patent Title: Sequencing or sample preparation instrument Mar. 12, 2019
  • Patent Title: Display screen or portion thereof with graphical user interface for a sequencing instrument Jan. 29, 2019
Government Contracts

Federal grants, loans, and purchases

Government Contracts

Estimated quarterly amount awarded to ILMN from public contracts

ILMN News

Recent insights relating to ILMN

CNBC Recommendations

Recent picks made for ILMN stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in ILMN

ILMN Analyst Ratings

ILMN Stock Forecasts
...

  • ... Highest Price Target
  • ... Median Price Target
  • ... Lowest Price Target
ILMN Analyst Forecasts
Analyst
Firm
Current
Previous
Date
Frequently Asked Questions
  • Is $ILMN stock a Buy, Sell, or Hold?

  • What is the price target for $ILMN stock?

* Analyst consensus is not financial advice. Please see our data disclaimers .

ILMN Top Shareholders
Shareholder
Shares Held
ILMN Options Owners
Shareholder
Security
Underlying Shares
Frequently Asked Questions
  • Who owns $ILMN stock?

  • Who owns the most shares of $ILMN stock?

  • What funds own $ILMN stock?

* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.

ILMN Stock Smart Score

The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.

The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?

Sign Up to view ILMN Smart Score

Score Breakdown
Bull Case vs Bear Case

See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.

Example:

Bulls Say:

The Bulls Say summary highlights positive aspects of the stock.

Bears Say:

The Bears Say summary points out potential risks and negative aspects of the stock.

Show More
About ILMN

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

  • Address San Diego, CA
  • Market Cap 17.9 billion
  • Employees 8,970
  • Industrial Classification Laboratory Analytical Instruments
Illumina Inc Executive Compensation
Name
Role
Salary
Bonus
Stock/Option Awards
Total Compensation